CRANAD 28

Confirm delete?

CRANAD 28

Zoom

Cat No: 19816

CRANAD 28 is a curcumin derivative and non-conjugated fluorescent affinity probe for the detection of amyloid-β (Aβ) in vitro and in vivo that has excitation/emission spectra of 498/578 nm, respectively.{40278} It binds to various forms of Aβ, includi...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

CRANAD28

Product Overview:
CRANAD 28 is a curcumin derivative and non-conjugated fluorescent affinity probe for the detection of amyloid-β (Aβ) in vitro and in vivo that has excitation/emission spectra of 498/578 nm, respectively.{40278} It binds to various forms of Aβ, including Aβ40 monomers and aggregates, as well as Aβ42 monomers, dimers, and oligomers (Kds = 68.8, 52.4, 159.7, 162.9, and 85.7 nM, respectively). When bound to Aβ, the fluorescence intensity decreases, in contrast to similar curcumin-based fluorescent probes. CRANAD 28 labels amyloid plaques and cerebral amyloid angiopathy both in APP/PS1 mouse brain sections and in live mice following i.v. administration. It also inhibits copper-induced and naturally occurring Aβ crosslinking.

Size	500 µg
Shipping	dry ice
CAS Number	1623747-97-6
Molecular Formula	C₂₇H₂₃BF₂N₄O₂
SMILES	[F-][B+3]1([F-])[O]=C([CH-]C(/C=C/C2=C(C)N(C3=CC=CC=C3)N=C2)=[O]1)/C=C/C4=C(C)N(C5=CC=CC=C5)N=C4
Molecular Weight	484,3
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2933.49
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.